Clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients: the SUCLINGEN study.
Navin Kumar LoganadanHasniza Zaman HuriShireene Ratna VethakkanZanariah HusseinPublished in: Pharmacogenomics (2020)
Background: Due to several limitations in the study designs of sulfonylurea pharmacogenomics studies, we investigated the clinical and genetic predictors of secondary sulfonylurea failure in Type 2 diabetes patients. Materials & methods: Patients receiving the maximum sulfonylurea and metformin doses for >1 year were enrolled. Secondary sulfonylurea failure was defined as HbA1c >7.0% (>53 mmol/mol) after a 12-month follow-up. Results: By multivariate analysis, increased insulin resistance (HOMA2-IR), baseline HbA1c >7.0%, residing in eastern Peninsular Malaysia, and the CC genotype of rs757110 ABCC8 gene polymorphism were independent predictors of secondary sulfonylurea failure (p < 0.05) while sulfonylurea-induced hypoglycemia was protective against such failure (p < 0.05). Conclusion: Sulfonylurea does not benefit patients with an increased risk of secondary sulfonylurea failure.
Keyphrases
- type diabetes
- end stage renal disease
- insulin resistance
- newly diagnosed
- ejection fraction
- chronic kidney disease
- glycemic control
- peritoneal dialysis
- adipose tissue
- prognostic factors
- metabolic syndrome
- emergency department
- gene expression
- genome wide
- dna methylation
- skeletal muscle
- high fat diet
- single molecule
- weight loss
- diabetic rats
- endothelial cells
- data analysis